ITN Trial Status

Last updated: August 10th, 2019
Yellow - Development: Starts with protocol writing and other tasks including site selection, contracting and preparation and submission of an IND.

Green - Enrollment: Starts with the activation of the first site and continue until the last participant has first visit (LPFV).

Blue - Follow up: all trial activity starting with LPFV and concludes with last participant, last visit (LPLV).

Red – Analysis: Starts when all visits have been complete and includes data clean-up, database lock and reporting of clinical results.
ITN076AD FEAST Pilot: Food Exposure Allergy Suppression. Phase II

ITN084AD GRADUATE: Subcutaneous grass pollen allergen immunotherapy. Phase II

ITN087AD EFFECT: EFFicacy of Etokimab in Peanut Allergy, a Randomized Controlled Trial. Phase II
ENROLLMENT

ITN070AD LEAP Trio: LEAP Participants and their families. Observational ClinicalTrials.gov

ITN079AD ACTIVATE: Exposure to Vaginal Microbiome in C-section Infants Phase II ClinicalTrials.gov

ANALYSIS

ITN050AD IMPACT: Peanut Oral Immunotherapy in Children Phase II ClinicalTrials.gov

ITN57AD CATNIP: Anti-TSLP Plus Antigen-Specific Immunotherapy for Induction of Tolerance in Individuals With Cat Allergy Phase II ClinicalTrials.gov
Autoimmune Trials - Development

**ITN077AI BEAT-MS**: BEst Available Therapy vs. Autologous Hematopoietic Stem Cell Transplant for MS. Phase II
- Development (12/16-10/19)
- Enrollment (10/19-09/22)
- Follow-up (09/22-09/28)
- Analysis (09/28-06/29)

**ITN080AI REBOOT**: Belimumab and Rituximab for Primary Membranous Nephropathy Phase II
- Development (01/17-02/22)
- Enrollment (10/19-01/23)
- Follow-up (01/23-01/26)
- Analysis (01/26-10/26)

**ITN086AI REVEAL**: Evaluation of AMG 714 for Vitiligo. Phase II
- Development (04/18-12/19)
- Enrollment (12/19-02/21)
- Follow-up (02/21-02/22)
- Analysis (02/22-11/22)
ENROLLMENT

ITN075AI BRAVOS: Brentuximab vedotin in diffuse cutaneous systemic sclerosis  Phase II  Clinicaltrials.gov

ANALYSIS

ITN055AI CALIBRATE: Rituximab and Belimumab for Lupus Nephritis  Phase II  Clinicaltrials.gov

ITN059AI PAUSE: Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris  Phase II  Clinicaltrials.gov
ENROLLMENT

ITN062ST TEACH: Tolerance by engaging antigen during cellular homeostasis  Phase II  Clinicaltrials.gov

ITN063ST ALLTOL: ALLograft TOLerance Study  Observational  Clinicaltrials.gov

ITN073ST LITTMUS MGH: Liver Transplantation with Tregs at MGH  Phase II  Clinicaltrials.gov
FOLLOW UP

ITN056ST OPTIMAL: Senescence and Exhaustion Biomarkers of Operational Tolerance Following IS Withdrawal in Liver Transplant Phase II Clinicaltrials.gov
ENROLLMENT

ITN066AI T1DES: Long-Term Investigative Follow-up on Type 1 Diabetes  Observational  [Clinicaltrials.gov]
FOLLOW UP

ITN058AI EXTEND: Preserving Beta Cell Function with Tocilizumab in New Onset Type 1 Diabetes  Phase II

Clinicaltrials.gov
ONGOING MECHANISTIC STUDY AND FOLLOW UP

ITN829AI  INTREXON : ActoBio AG019 (L. lactis) and teplizumab  
Clinicaltrials.gov

ITN803ST  deLTa:  darTregs in Liver Transplantation  
Clinicaltrials.gov

ITN823ST  IWITH  Immunosuppression Withdrawal for Stable Pediatric Liver Transplant Recipients  
Clinicaltrials.gov